Option chain shows key data for FUJIFILM Holdings's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for FUJIFILM Holdings.

FUJIFILM Holdings (OTC:FUJIY) Stock, Option Chain

FUJIFILM HLDGS CORP

FUJIFILM Holdings

FUJIFILM Holdings Corp offers products and services used in photo development and film and photo taking processes. The company produces color films and single use cameras, color paper and chemicals, photofinishing equipment, film and photo processing services, electronic imaging such as digital cameras, optical devices such as camera modules for mobile phones, TV camera lenses and cine lenses, x-ray imaging systems and films, inkjet printers, flat panel materials, recording storage mediums such as data cartridges and videotape products, and office products such as office printers. The document solutions segment including office printers and the information solutions segment consisting of its x-ray imaging and data storage systems form most of the group's yearly revenue stream.

Biotech

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Government

Large Cap

News

Health Care

Commodities

Legal

Markets

Movers

Tech

Media

Trading Ideas

General

$BTC

$ETH

European Aeronautic Defence And Space Unsponsored

EADSY

FUJIF

FUJIY

JBLU

NFLX

SHEL

STLA

TSLA

TWTR

Reuters

Twitter Says Elon Musk Under Federal Probe Over $44B Twitter Deal, In Court Filing

Biden Asked OPEC+ To Delay Output Decision, Elon Musk Faces Federal Probe Over Twitter Deal, Netflix Ad-Supported Plan: Top Stories Friday, Oct. 14

Once Favored By Late Shinzo Abe, Japan Culls Development On Repurposed COVID-19 Treatment

Penny Stocks

Financing

Small Cap

ACAD

ARGX

ATRA

BTAI

FLDM

FULC

HTGC

ISBC

RCUS

SAGE

TBPH

TFFP

VRDN

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:

The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel

FUJIFILM HLDGS CORP ADR by FUJIFILM Holdings Corp.

FUJIFILM Holdings Corp

FUJIFILM Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUJIY#OTC">FUJIY</a>) is looking for FY2024 GAAP EPS of $1.39. Raises FY2024 sales outlook from $19.97 billion to $21.16 billion.

Guidance

FUJIFILM Holdings expects FY2024 Revenue of JPY 3150B; EPS JPY 207.50.

FUJIFILM Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUJIY#OTC">FUJIY</a>) reported quarterly earnings of $0.28 per share. This is a 64.71 percent increase over earnings of $0.17 per share from the same period last year. The company reported $5.14 billion in sales this quarter. This is a 2.14 percent increase over sales of $5.04 billion the same period last year.

Earnings

FUJIFILM Holdings Q2 EPS $0.28 Up From $0.17 YoY, Sales $5.14B Up From $5.04B YoY

Reuters
<a class="editor-rtfLink" href="https://www.benzinga.com/news/22/10/29263575/elon-musk-under-federal-probe-over-44b-twitter-deal-reveals-court-filing" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Twitter Says Elon Musk Under Federal Probe Over $44B Twitter Deal, In Court Filing</a>
<ul>
<li>Tesla Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) CEO Elon Musk is reportedly under investigation by federal authorities over his bid to purchase Twitter Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/twtr#NASDAQ">TWTR</a>).</li>
<li>Twitter said in a court filing released Thursday that Musk&rsquo;s attorneys claimed &ldquo;investigative privilege&rdquo; while refusing to hand over material sought by the social media company.</li>
<li>The lawyers had reportedly provided a &ldquo;privilege log&rdquo; to Twitter in September, which identified documents to be withheld.</li>
</ul>
<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/22/10/29266500/novartis-fails-to-prevent-generic-competition-for-its-blockbuster-multiple-sclerosis-drug" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Novartis Fails To Prevent Generic Competition For Its Blockbuster Multiple Sclerosis Drug</a>
<ul>
<li>The U.S. Supreme Court rejected Novartis AG&rsquo;s (NYSE: <a class="editor-rtfLink" href="https://www.benzinga.com/stock/nvs#NYSE" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">NVS</a>) effort to block the launch of generic versions of its multiple sclerosis drug Gilenya.</li>
<li>Novartis had asked the justices to suspend a lower court&rsquo;s ruling that lifted a ban on generic versions of Gilenya.</li>
</ul>
<a class="editor-rtfLink" href="https://www.benzinga.com/news/22/10/29265196/stellantis-unit-agrees-to-pay-5-6m-in-california-emissions-probe" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Stellantis Unit Agrees To Pay $5.6M In California Emissions Probe</a>
<ul>
<li>The state of California said a unit of Stellantis NV (NYSE: <a class="editor-rtfLink" href="https://www.benzinga.com/stock/stla#NYSE" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">STLA</a>), FCA U.S. will pay $5.6 million to resolve a violation of air quality regulations in California.</li>
<li>The California Air Resources Board said there were 30,600 vehicles involved in the settlement, including 2012 &ndash; 2018 model Ram 1500, Jeep Grand Cherokee, and Dodge Durango.</li>
<li>The vehicles involved were fitted with 5.7L gasoline engines that purportedly did not comply with emission standards.</li>
</ul>
<a class="editor-rtfLink" href="https://www.benzinga.com/news/22/10/29266890/airbus-and-qatar-airways-legal-quarrel-over-a350-intensifies" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Airbus and Qatar Airways Legal Battle Over A350 Intensifies</a>
<ul>
<li>Airbus SE and Qatar Airways clashed in court in a dispute over damage to A350 jetliners.</li>
<li>Qatar Airways is suing Airbus over damage to the painted surface and anti-lightning system on A350 jets, saying safety could be at risk from a design defect.</li>
<li>The two companies must provide documents about their claims as the dispute is headed toward a London aerospace trial in mid-2023 if no settlement is reached.</li>
</ul>

Wall Street Journal
<a class="editor-rtfLink" href="https://www.benzinga.com/markets/cryptocurrency/22/10/29264859/bitcoin-broker-nydig-lays-off-110-employees-to-trim-expenses" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Bitcoin Broker NYDIG Lays Off 110 Employees To &lsquo;Trim Expenses&rsquo;</a>
<ul>
<li>Bitcoin (BTC/USD) trading platform NYDIG laid off about a third of its employees on Sep. 22, numbered around 110.</li>
<li>The company executives told the laid-off employees that it decided to cut down on expenses and focus on more businesses.</li>
<li>NYDIG CEO Robert Gutmann and President Yan Zhao stepped down from their roles on Oct. 3, replaced by Tejas Shah and Nate Conrad, respectively.</li>
</ul>
<a class="editor-rtfLink" href="https://www.benzinga.com/news/large-cap/22/10/29265713/3ms-lawsuit-hit-earplug-unit-earns-faster-review-for-bankruptcy-ruling" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">3 M&rsquo;s Lawsuit Hit-Earplug Unit Earns Faster Review For Bankruptcy Ruling</a>
<ul>
<li>Judges from the U.S. Court of Appeals in Chicago granted 3M Co&rsquo;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mmm#NYSE">MMM</a>) bankrupt subsidiary, Aearo Technologies, a quicker-than-normal process for the review of the bankruptcy-court ruling.</li>
<li>The nod puts more than 230,000 lawsuits accusing the company of harming U.S. soldiers on a faster track to resolution.</li>
</ul>
<a class="editor-rtfLink" href="https://www.benzinga.com/news/22/10/29266158/bankruptcy-judge-ruled-in-support-of-375m-creditor-lawsuit-against-morgan-stanley" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Bankruptcy Judge Ruled In Support Of $375M Creditor Lawsuit Against Morgan Stanley</a>
<ul>
<li>Morgan Stanley (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ms#NYSE">MS</a>) creditors can move forward with a lawsuit over dividends paid before the grocery chain Tops Friendly Markets filed for chapter 11.</li>
<li>The creditors filed the claims in 2020 against Morgan Stanley Investment Management and other former owners of Tops, alleging the private equity owners paid themselves $375 million in dividends while leaving Tops insolvent.</li>
<li>Bankruptcy Judge Robert Drain highlighted how the bankruptcy code allows private equity owners to &ldquo;loot privately-held companies to the detriment of their non-insider creditors with effective impunity.&rdquo;</li>
</ul>

Bloomberg
<a class="editor-rtfLink" href="https://www.benzinga.com/government/22/10/29266594/american-jetblue-alliance-antitrust-case-gains-steam-as-court-seeks-more-documents" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">American-JetBlue Alliance Antitrust Case Gains Steam As Court Seeks More Documents</a>
<ul>
<li>The Justice Department sued American Airlines Group, Inc (NASDAQ: <a class="editor-rtfLink" href="https://www.benzinga.com/stock/aal#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">AAL</a>) and JetBlue Airways Corp (NASDAQ: <a class="editor-rtfLink" href="https://www.benzinga.com/stock/jblu#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">JBLU</a>) in 2021, terming their alliance as a &ldquo;merger&rdquo; that increased fares with reduced choice for passengers.</li>
<li>Senior airline executives from competitors testified that the alliance made it harder for them to compete in Boston and New York.</li>
<li>The U.S. District Judge sought metrics illustrating changes within the two carriers&rsquo; fleets and routes serving New York City and Boston before and since their Northeast Alliance.</li>
</ul>
<a class="editor-rtfLink" href="https://www.benzinga.com/news/22/10/29265692/bull-market-in-chinese-stocks-like-alibaba-is-round-the-corner-hedge-funds-say" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Bull Market In Chinese Stocks Like Alibaba Is Round The Corner, Hedge Funds Say</a>
<ul>
<li>Top Chinese macro hedge fund Shanghai Banxia Investment Management Center said the nation&rsquo;s stocks rout had run its course, predicting a bull market is around the corner. It rebuilt net-long positions in the mainland-traded A-share market to 40%.</li>
<li>Shanghai Yunhan Asset Management Co, another macro fund, started buying stocks oil, shipping, and medical equipment sectors. President Zhang Wenchao said that a weak economic recovery is inevitable, even in a worst-case scenario.</li>
</ul>
<a class="editor-rtfLink" href="https://www.benzinga.com/news/22/10/29265779/united-airlines-close-to-finalizing-triple-digit-order-for-widebody-jets" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">United Airlines Close To Finalizing Triple-Digit Order For Widebody Jets</a>
<ul>
<li>United Airlines Holdings Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ual#NASDAQ">UAL</a>) is likely closing in on orders for more than 100 widebody jets as it considers offers for Boeing Co&rsquo;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ba#NYSE">BA</a>) 787 Dreamliner and Airbus SE&rsquo;s (OTC: <a class="editor-rtfLink" href="https://www.benzinga.com/stock/eadsy#OTC" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">EADSY</a>) A350.</li>
<li>When finalized, the deal would be one of the largest ever purchases made for long-range aircraft.</li>
<li>United CEO Scott Kirby recently told pilots in a training session about the triple-digit order.</li>
</ul>

Benzinga
<a class="editor-rtfLink" href="https://www.benzinga.com/government/22/10/29263208/saudi-arabia-hints-biden-administration-suggested-delaying-opec-output-decision-by-a-month-it-would" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Saudi Arabia Says Team Biden Asked OPEC+ To Delay Output Decision By A Month, But It Would&rsquo;ve Had &lsquo;Negative Consequences&rsquo;</a>
<ul>
<li>Saudi Arabia has hinted that the Biden Administration had suggested delaying the decision by the Organization of the Petroleum Exporting Countries and its allies (OPEC+) to reduce its production output by a month, which it believed &ldquo;would have had negative economic consequences.&rdquo;</li>
<li>&ldquo;The Government of the Kingdom of Saudi Arabia ... clarified through its continuous consultation with the U.S. Administration that all economic analyses indicate that postponing the OPEC+ decision for a month, according to what has been suggested, would have had negative economic consequences,&rdquo; Saudi Arabia said.</li>
</ul>
<a class="editor-rtfLink" href="https://www.benzinga.com/news/22/10/29263147/elon-musk-says-starlink-satellite-internet-faced-relentless-jamming-attacks-spacex-relentless-cyberw" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Elon Musk Says Starlink, SpaceX Faced&rsquo; Relentless Jamming, Cyberwar,&rsquo; Courtesy Russia</a>
<ul>
<li>Tesla Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) CEO Elon Musk, who also heads SpaceX, said Thursday that Starlink faced &ldquo;relentless jamming.&rdquo;</li>
<li>Musk&rsquo;s comments came on Twitter in response to a user who asked Musk about Russian media claims that the country used the Tirada-2S satellite communications electronic jamming system against Starlink.</li>
</ul>
<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/22/10/29266009/once-favored-by-late-shinzo-abe-japan-culls-development-on-repurposed-covid-19-treatment" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Once Favored By Late Shinzo Abe, Japan Culls Development On Repurposed COVID-19 Treatment</a>
<ul>
<li>Fujifilm Holdings Corp (OTC: <a class="editor-rtfLink" href="https://www.benzinga.com/stock/fujiy#OTC" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">FUJIY</a>) (OTC: <a class="editor-rtfLink" href="https://www.benzinga.com/stock/fujif#OTC" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">FUJIF</a>) has discontinued the development of its anti-influenza drug, Avigan (favipiravir), for use as a therapeutic drug against COVID-19.</li>
<li>In 2021, Fujifilm Toyama Chemical began a phase 3 clinical trial in Japan with a target enrollment of 316 subjects. However, enrollment was terminated at 84 subjects.</li>
<li>The company said that subsequent analysis of data from 84 people enrolled in the trial showed no significant results.</li>
</ul>
<a class="editor-rtfLink" href="https://www.benzinga.com/news/large-cap/22/10/29266197/shell-joins-forces-with-singapore-renewables-firm-for-battery-storage-project-in-australia" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Shell Joins Forces With Singapore Renewables Firm For Battery Storage Project In Australia</a>
<ul>
<li>AMPYR Australia Pty Ltd and Shell Plc&rsquo;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/shel#NYSE">SHEL</a>) subsidiary Shell Energy Australia have signed a joint development agreement for a proposed battery energy storage system (BESS) in Australia.</li>
<li>The proposed 500-megawatt battery project will be built in Wellington (the Wellington BESS), Central West New South Wales.</li>
<li>The construction is expected to begin in mid-2023, subject to all relevant approvals and financing.</li>
</ul>
<a class="editor-rtfLink" href="https://www.benzinga.com/news/large-cap/22/10/29266605/kroger-albertsons-finally-seal-the-rumored-merger-deal-see-highlights" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Kroger, Albertsons Finally Seal The Rumored Merger Deal: See Highlights</a>
<ul>
<li>Putting all rumors at rest, Kroger Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kr#NYSE">KR</a>) and Albertsons Companies Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aci#NYSE">ACI</a>) have agreed to merge to establish a national footprint. </li>
<li>Kroger will acquire Albertsons for $34.10 per share, implying a total enterprise value of approximately $24.6 billion, including approximately $4.7 billion of Albertsons&rsquo; net debt. </li>
</ul>
<a class="editor-rtfLink" href="https://www.benzinga.com/news/22/10/29266560/french-food-company-danone-to-dismiss-russian-dairy-business-incur-1b-loss" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">French Food Company Danone To Dismiss Russian Dairy Business; Incur &euro;1B Loss</a>
<ul>
<li>French food company Danone SA (OTC: GPDNF) has decided to initiate a process to transfer the effective control of its Essential Dairy and Plant-based business in Russia.</li>
<li>The transaction could result in a write-off of up to &euro;1 billion.</li>
<li>The company decided as it felt the best option to ensure long-term local business continuity for its employees, consumers, and partners.</li>
</ul>
<a class="editor-rtfLink" href="https://www.benzinga.com/news/earnings/22/10/29266904/unitedhealth-q3-beat-street-raises-fy22-profit-guidance" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">UnitedHealth Q3 Beat Street, Raises FY22 Profit Guidance</a>
<ul>
<li>UnitedHealth Group Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unh#NYSE">UNH</a>) has reported <a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/22/10/b29265398/unitedhealth-group-reports-third-quarter-2022-results" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Q3 FY22 sales of $80.89 billion</a>, up 12% Y/Y, beating the consensus of $80.50 billion.</li>
<li>The company said Q3 growth was driven by continued expansion in the number of people served throughout UnitedHealthcare and in the value-based care initiatives at Optum Health.</li>
<li>Adjusted EPS of $5.79 increased 28% Y/Y, surpassing the consensus of $5.42.</li>
</ul>
<a class="editor-rtfLink" href="https://www.benzinga.com/general/entertainment/22/10/29262057/heres-how-much-netflixs-ad-supported-plan-costs-and-how-it-compares-to-rivals" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Here&rsquo;s How Much Netflix&rsquo;s Ad-Supported Plan Costs And How It Compares To Rivals</a>
<ul>
<li>The battle for consumers&rsquo; money for streaming platforms continues to heat up, and several ad-supported lower-priced plans could increase the market dynamics even more.</li>
<li>Here&rsquo;s a look at how the prices of several top streaming platforms stack up and when consumers can pay for a cheaper Netflix Inc (NASDAQ: <a class="editor-rtfLink" href="https://www.benzinga.com/stock/nflx#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">NFLX</a>) and Disney+ plan.</li>
<li>The launch of a highly anticipated ad-supported plan from Netflix has a release date and price.</li>
</ul>

<ul>
<li>Fujifilm Holdings Corp&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/fujiy#OTC">FUJIY</a>) (OTC: <a class="ticker" href="https://www.benzinga.com/stock/fujif#OTC">FUJIF</a>) has&nbsp;<a class="editor-rtfLink" href="https://www.fujifilm.com/jp/en/news/hq/8698" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">discontinued</a>&nbsp;the development of its anti-influenza drug, Avigan (favipiravir), for use as a therapeutic drug against COVID-19.</li>
<li>In 2021, Fujifilm Toyama Chemical began a phase 3 clinical trial in Japan with a target enrollment of 316 subjects to confirm Avigan&#39;s efficacy in preventing the progression to severe symptoms in COVID-19 patients who have not yet been vaccinated.&nbsp;</li>
<li>However, enrollment was terminated at 84 subjects in March 2022 following a change of circumstances, including improvement in the vaccination rate and the spread of the Omicron variants, which have lower symptom severity rates than conventional strains.&nbsp;</li>
<li>The company said that subsequent analysis of data from 84 people enrolled in the trial showed no significant results.</li>
<li>At the time, Prime Minister Shinzo Abe had hoped for early approval of the drug and pledged to donate it to needy countries, Reuters&nbsp;<a class="editor-rtfLink" href="https://www.reuters.com/business/healthcare-pharmaceuticals/japans-fujifilm-discontinues-development-avigan-covid-19-drug-2022-10-14/" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">reported</a>. Abe, who left office in 2020, was assassinated in July during a political rally.</li>
</ul>

&nbsp;
FUJIFILM Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUJIY#OTC">FUJIY</a>) reported its Q4 earnings results on Wednesday, May 11, 2022 at 02:00 AM.
Here&#39;s what investors need to know about the announcement.
<h3>Earnings</h3>
FUJIFILM Holdings beat estimated earnings by 90.16%, reporting an EPS of $1.16 versus an estimate of $0.61.
Revenue was down $118.00 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.36 which was followed by a 3.0% drop in the share price the next day.
Here&#39;s a look at FUJIFILM Holdings&#39;s past performance:
&nbsp;
<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2022</th>
<th>Q2 2022</th>
<th>Q1 2022</th>
<th>Q4 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.98</td>
<td>0.67</td>
<td>0.53</td>
<td>0.95</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.34</td>
<td>0.88</td>
<td>1.30</td>
<td>1.30</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>5.46B</td>
<td>5.38B</td>
<td>5.00B</td>
<td>5.64B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>5.77B</td>
<td>5.67B</td>
<td>5.30B</td>
<td>5.84B</td>
</tr>
</tbody>
</table>
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
FUJIFILM Holdings management provided guidance for FY 2023, expecting earnings between $4.239 and $4.239 per share.
To track all earnings releases for FUJIFILM Holdings <a href="https://www.benzinga.com/quote/FUJIY/earnings">visit their earnings calendar here.</a>
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

FUJIFILM Holdings: Q4 Earnings Insights

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:
<h3>Stocks In Focus</h3>
<h3>Theravance Announces Phase 3 Data For Ampreloxetine Showing Clear Benefit In Multiple System Atrophy Patients</h3>
Theravance Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tbph#NASDAQ">TBPH</a>) announced results from the second Phase 3 study, assessing the durability of clinical effect of ampreloxetine compared to placebo for the treatment of symptomatic neurogenic orthostatic hypotension.
The primary endpoint was not statistically significant for the overall population of patients, which included patients with Parkinson&#39;s disease, pure autonomic failure and multiple system atrophy. Yet the pre-specified subgroup analysis by disease type suggests the benefit seen in patients receiving ampreloxetine was largely driven by MSA patients.
The stock was advancing 5.26% to $10 in premarket trading.
<h3>Novartis Receives Approval To Manufacture Zolgensma In Second Manufacturing Facility In US</h3>
Novartis AG (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvs#NASDAQ">NVS</a>) said the U.S. Food and Drug Administration has granted commercial licensure approval for its Durham, North Carolina site, a multiproduct gene therapy manufacturing facility. This approval allows the&nbsp;170,000 square-foot facility to make, test and release commercial <a href="https://www.benzinga.com/general/biotech/19/05/13617620/whats-the-buzz-around-novartis-gene-therapy-zolgensma"> Zolgensma, </a>as well as produce gene therapy product for current and future clinical trials, the company said.&nbsp;
The clearance brings online the second commercially licensed manufacturing facility for Novartis Gene Therapies, joining the Libertyville, Illinois&nbsp;site.
<h3>Fluidigm Announces Completion Of Strategic Capital Infusion, Renaming To Standard BioTools</h3>
Fluidigm Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fldm#NASDAQ">FLDM</a>) announced the closing of the previously announced strategic capital infusion from Casdin Capital&nbsp;and Viking Global. The company also announced its renaming to Standard BioTools Inc. Its common stock is expected to begin trading on Nasdaq under the symbol &quot;LAB&quot; beginning on Wednesday.
Standard BioTools, the company said, will focus on significantly advancing its mission to become an essential solutions partner to the life science industry focused on the highest growth areas of biological discovery and development.
<h3>Argenx Announces Positive Long-Term Data For Vyvgart In Generalized Myasthenia Gravis</h3>
Argenx (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/argx#NASDAQ">ARGX</a>) announced interim results from an ADAPT+ Phase 3&nbsp;three-year extension study evaluating the long-term safety, tolerability and efficacy of <a href="https://www.benzinga.com/general/biotech/21/12/24693779/argenxs-vyvgart-wins-fda-approval-for-autoimmune-neuromuscular-disease"> Vyvgart </a> for the treatment of adults with generalized myasthenia gravis.
&quot;Patients who participated in ADAPT+ continued to experience consistent efficacy and safety over a year of treatment, reinforcing the potential benefit this targeted therapy can offer to this community,&quot; said James Howard, principal investigator of the study.
The stock was up 1.41% at $328.99 in premarket trading.
Related Link: <a href="https://www.benzinga.com/general/biotech/22/04/26440198/the-week-ahead-in-biotech-april-3-april-9-bioxcel-fda-decision-neurology-conference-presentations"> The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight </a>
<h3>Bristol-Myers Squibb Snags Approval For Opdivo/Opdivo Combo In Two Cancer Indications In Europe</h3>
Bristol-Myers Squibb Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bmy#NYSE">BMY</a>) announced three approvals in Europe. The company said European Commission (EC) has approved Opdivo in combination with fluoropyrimidine- and platinum-based chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) with tumor cell PD-L1 expression, equal to or more than 1%.
The regulator also approved Opdivo combination with Yervoy for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic ESCC with tumor cell PD-L1 expression equal to or more than 1%.
Opdivo was also approved as an adjuvant treatment of adults with muscle-invasive urothelial carcinoma with tumor cell PD-L1 expression equal to or more than 1%, who are at a high risk of recurrence after undergoing radical resection.
<h3>Arcus Biosciences To Join S&amp;P SmallCap 600 Index</h3>
Arcus Biosciences, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rcus#NYSE">RCUS</a>) will replace Investors Bancorp Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isbc#NASDAQ">ISBC</a>) in the S&amp;P SmallCap 600 effective prior to the opening of trading on Thursday, according to S&amp;P Dow Jones Indices.
Arcus stock was advancing 13.13% to $39.47 in premarket trading.
<h3>Atara Completes Sale Of Cell Therapy Manufacturing Unit to Fujifilm Subsidiary</h3>
Atara Biotherapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atra#NASDAQ">ATRA</a>) announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Holdings Corporation (OTC: <a class="ticker" href="https://www.benzinga.com/stock/fujiy#OTC">FUJIY</a>), has completed the acquisition of Atara&#39;s cell therapy manufacturing facility in Thousand Oaks, California for $100 million upfront and the commencement of a long-term strategic supply agreement. This partnership and acquisition were first announced in January.
The agreement is expected to reduce Atara&#39;s planned operating expenses over the multiyear partnership period. The upfront consideration, along with the reduction in operating expenses, in addition to Atara&#39;s existing cash, cash equivalents and short-term investments is expected to fund Atara&#39;s planned operations into the fourth quarter of 2023.
<h3>Viridian Strikes Agreement For Up to $75M In Debt Financing</h3>
Viridian Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrdn#NASDAQ">VRDN</a>) said it has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/htgc#NYSE">HTGC</a>) for up to $75 million.
<h3>TFF Pharma Gains On Insider Buying</h3>
TFF Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tffp#NASDAQ">TFFP</a>) disclosed in two separate filings that two of its directors bought shares in the company or stock option to buy common stock.
The stock was adding 6.32% to $7.40 in premarket trading.
Click <a href="https://www.benzinga.com/fda-biotech#historical"> here </a> to access Benzinga&#39;s FDA Calendar.
<h3>On The Radar</h3>
<h3>PDUFA Dates</h3>
The FDA is scheduled to rule on BioXcel Therapeutics, Inc.&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btai#NASDAQ">BTAI</a>) new drug application for BXCL501 is an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation associated with neuropsychiatric disorders.
<h3>Clinical Readouts/Presentations</h3>
American Academy of Neurology Annual Meeting Presentations
Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>): Phase 2 data for losamapimod in patients with facioscapulohumeral muscular dystrophy
Sage Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sage#NASDAQ">SAGE</a>): data from the Phase 2 Luminary study of SAGE-718 in patients with mild cognitive impairment (MCI) and mild dementia due to Alzheimer&#39;s disease
ACADIA Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acad#NASDAQ">ACAD</a>): Phase 3 efficacy and safety of trofinetide for the treatment of Rett syndrome
Related Link: <a href="https://www.benzinga.com/general/biotech/22/03/26260100/merck-continues-to-see-executive-exodus-heres-a-look-at-all-recent-departures"> Merck Continues to See Executive Exodus; Here&#39;s A Look At All Recent Departures </a>

&nbsp;
FUJIFILM Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUJIY#OTC">FUJIY</a>) reported its Q3 earnings results on Wednesday, February 9, 2022 at 02:00 AM.
Here&#39;s what investors need to know about the announcement.
<a href="https://www.benzinga.com/trading-ideas/long-ideas/22/02/25501195/executives-buy-around-64m-of-3-stocks">Check out this: Executives Buy Around $64M Of 3 Stocks </a>
<h3>Earnings</h3>
FUJIFILM Holdings beat estimated earnings by 36.73%, reporting an EPS of $1.34 versus an estimate of $0.98.
Revenue was up $258.00 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.21, which was followed by a 0.9% drop in the share price the next day.
Here&#39;s a look at FUJIFILM Holdings&#39;s past performance:
&nbsp;
<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2022</th>
<th>Q1 2022</th>
<th>Q4 2021</th>
<th>Q3 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.67</td>
<td>0.53</td>
<td>0.95</td>
<td>0.95</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.88</td>
<td>1.30</td>
<td>1.30</td>
<td>1.40</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>5.38B</td>
<td>5.00B</td>
<td>5.64B</td>
<td>5.64B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>5.67B</td>
<td>5.30B</td>
<td>5.84B</td>
<td>5.51B</td>
</tr>
</tbody>
</table>
To track all upcoming earnings announcements, click to use <a href="https://www.benzinga.com/calendars/earnings">Benzinga Earnings Calendar</a>.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

Recap: FUJIFILM Q3 Earnings

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:
<h3>Stocks In Focus</h3>
<h3>Atara To Sell Manufacturing Plant to Fuji&#39;s CDMO Unit For $100M</h3>
Atara Biotherapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atra#NASDAQ">ATRA</a>) announced that it has entered into a long-term strategic agreement with FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Holdings Corporation (Pink: <a class="ticker" href="https://www.benzinga.com/stock/fujiy#Pink">FUJIY</a>), under which Fujifilm will acquire Atara&#39;s T-Cell Operations and Manufacturing facility in Thousand Oaks, California for $100 million upfront, retaining current manufacturing and quality staff at the site.
Following completion of the transaction, FDB will provide Atara with access to the flexible capacity and specific capability needed to manufacture clinical and commercial-stage allogeneic cell therapies for its maturing pipeline.
Atara shares was adding 8.79% to $16.59 in premarket trading.
<h3>Galapagos Appoints Paul Stoffels As CEO</h3>
Galapagos NV (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glpg#NASDAQ">GLPG</a>) announced the appointment of Dr. Paul Stoffels as chief executive officer, effective April 1, 2022. Previously, Stoffels was vice chairman of the executive committee and chief scientific officer of Johnson &amp; Johnson, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>), where he spearheaded the company&#39;s research and product pipeline.
The <a href="https://www.benzinga.com/news/22/01/25254007/26-stocks-moving-in-thursdays-pre-market-session"> stock </a> was climbing 12.08% to $59.76 in premarket trading.
<h3>Aridis Lands&nbsp;Gates Foundation Funding For Technology To Deliver Inhaled Formulation Of Monoclonal Antibodies Against COVID,&nbsp;Flu Viruses</h3>
Aridis Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ards#NASDAQ">ARDS</a>) said it received a grant award from the Bill &amp; Melinda Gates Foundation to evaluate the application of its inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and SARS-CoV2 to people in low- and middle-income countries.
The $1.9-million award will fund the preclinical development of stabilized liquid aerosols and room temperature stable inhalable dry powders containing anti-influenza and anti-SARS-CoV2 mAbs that are manufactured from spirulina algae. It also funds animal safety and efficacy testing in virus challenge animal models. Pending the outcome of preliminary results, the Gates Foundation has the option to continue funding through preclinical IND enabling activities and through a Phase 1/2a human clinical trial.
The stock was up 32.76% at $2.31 in premarket trading.
<h3>Atai Launches New Platform Company Focused On Mental Health Treatments</h3>
Atai Life Sciences N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atai#NASDAQ">ATAI</a>) announced the launch of Invyxis, a new, wholly owned platform company committed to developing new chemical entities and to further pioneering next-generation mental health treatments. Invyxis will bring proven medicinal chemistry tools and comprehensive biological screening approaches to atai&#39;s growing enterprise of drug discovery and design, the company said.&nbsp;
The stock was seen moving up 7.58% to $5.25 in premarket trading.
Related Link: <a href="https://www.benzinga.com/general/biotech/22/01/25176010/the-week-ahead-in-biotech-jan-23-29-roche-azurity-fda-decisions-j-j-vertex-earnings-samsara-visio">The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&amp;J, Vertex Earnings, Samsara Vision IPO And More </a>
<h3>Oncolytics&#39; Chinese Partner Reports Positive Data From Dose-Escalation Study Of Immunotherpay-Chemo Combo In Breast Cancer</h3>
Oncolytics Biotech Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/oncy#NASDAQ">ONCY</a>) announced that its partner Adlai Nortye has advanced to the second of three dose escalation cohorts in the bridging clinical trial evaluating the safety, tolerability&nbsp;and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer.
Dosing in the trial&#39;s first dose escalation cohort is complete and no safety issues have been reported. The second dose escalation cohort is the equivalent dose that was administered in the IND-213 study, which reported a near doubling of survival in HR+/HER2- metastatic breast cancer patients.
Oncolytics shares were rising 8.74% to $1.99 in premarket trading.
<h3>Cue Biopharma Reports Early Stage Data From Monotherapy and Combo Study Of CUE-101 In Head And Neck Squamous Cell Carcinoma</h3>
Cue Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cue#NASDAQ">CUE</a>) said early data from the Phase 1 combination study of CUE-101 and Merck &amp; Co., Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrk#NYSE">MRK</a>) supported synergistic activity, with two of the four patients treated in dose escalation in two cohosts showing partial responses. Two are manifesting reduction in target lesions, it added. The combo is being evaluated as a treatment option for third line and beyond HPV+ recurrent/metastatic head and neck squamous cell carcinoma.
The company also noted that updated CUE-101 monotherapy data further enhances confidence in potential as single agent therapeutic with 50% clinical benefit rate reported to date in RP2D (4mg/kg) expansion monotherapy trial and an emerging enhanced overall survival rate that supports the premise that CUE-101 selectively stimulates cancer-relevant CD8+ T cells.
The stock was slipping 2.83% to $10.30 in premarket trading.
<h3>Moderna Commences Phase 2 Study Of Omicron-Specific COVID Booster Vaccine Candidate</h3>
Moderna, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) <a href=" https://www.benzinga.com/general/biotech/22/01/25253578/after-pfizer-moderna-kickstarts-omicron-targeted-covid-19-vaccine-trial"> announced </a>the first participant has been dosed in the Phase 2 study of its omicron-specific booster candidate.
The stock was gaining 3.25% to $160 in premarket trading.
Click <a href="https://www.benzinga.com/fda-biotech#historical"> here </a> to access Benzinga&#39;s FDA Calendar.
<h3>Offerings</h3>
Zymeworks, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zyme#NASDAQ">ZYME</a>) priced its underwritten public offering of 9.16 million common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3.34 million common shares. The common shares are being offered at a public offering price of $8 per common share and the pre-funded warrants are being offered at a public offering price of $7.9999 per pre-funded warrant. The gross proceeds to Zymeworks from the offering are expected to be approximately $100 million.
The stock was slipping 14.59% to $7.96 in premarket trading.
<h3>On The Radar</h3>
<h3>Earnings</h3>
ResMed Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rmd#NYSE">RMD</a>) (after the close) 
Taro Pharmaceutical Industries Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/taro#NYSE">TARO</a>) (after the close)
Related Link: <a href=" https://www.benzinga.com/general/biotech/21/12/24733823/attention-biotech-investors-mark-your-calendar-for-january-pdufa-dates"> Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates </a>

Offerings

ARDS

ATAI

GLPG

MRNA

ONCY

TARO

ZYME

The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study

Benzinga&rsquo;s latest Stock Wars matches up two leaders in a major industry sector, with the goal of letting readers decide which company is the better investment.
This week, the duel is between two old-school titans of the tech world: IBM (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ibm#NYSE">IBM</a>) and Xerox Holdings Corp&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xrx#NYSE">XRX</a>).
Big Blue Blossoms: On June 16, IBM will be celebrating its 110th year in business. Originally known as the Computing-Tabulating-Recording Company, it became International Business Machines in 1924; the company&rsquo;s thick-lettered logo gave it the nickname &ldquo;Big Blue.&rdquo;
<img alt="ibm.png" src="https://www.benzinga.com/files/u200644/ibm.png" style="height:128px; width:320px" />
Over the past year, the Armonk, New York-headquartered IBM has acquired nine privately-held companies, including the cloud computing consultancy Taos, the Salesforce consultancies 7Summits and Waeg, the cloud cybersecurity provider Spanugo and the Brazil-based WDG Automation.
Last October, the company announced it would split into two entities with the IBM operation concentrating on cloud computing and artificial intelligence solutions and a newly-formed company called Kyndryl that would become &ldquo;the world&rsquo;s leading managed infrastructure services provider,&rdquo; with relationships involving more than 4,600 clients in 115 countries.
While it reshapes corporate operations, it has also been busy on the tech front. Earlier this month, IBM <a href="https://www.benzinga.com/news/21/05/20989845/ibm-unveils-2-nanometer-semiconductor-chip-technology">introduced</a> the first semiconductor chip with 2-nanometer nanosheet technology, which the company said would achieve a 45% higher performance level &mdash; or 75% lower energy use &mdash; than the most advanced 7 nm node chips now in use.
IBM has also been laying the groundwork for a new generation of tech professionals via a new quantum education initiative with the nation&rsquo;s historically black colleges and universities and with an IT Infrastructure apprenticeship accelerator program designed to recruit and develop candidates who have no previous experience working in the technology field.
In its Q1 earnings announced last month, IBM reported $17.7 billion in revenue, a 1% year-over-year increase and the first increase after four consecutive quarters of revenue declines. The company&rsquo;s earnings per share (EPS) for the quarter were $1.06 a share and non-GAAP EPS was $1.77.
Among its business segments, it recorded positive quarterly revenue of $5.4 billion for its cloud and cognitive software business (up 3.8%), $4.2 billion for its global business services, including consulting and application management (up 2.4%), and $1.4 billion for its systems business, including hardware and operating systems software (up 2.2%).
But there were quarterly year-over-year declines for its global technology services, which include infrastructure and cloud services and technology support services ($6.4 billion, down 1.5%) and its global financing segment that includes financing and used equipment sales (revenues of $240 million, down 20%).
&ldquo;Strong performance this quarter in cloud, driven by increasing client adoption of our hybrid cloud platform, and growth in software and consulting enabled us to get off to a solid start for the year,&quot; said Arvind Krishna, IBM chairman and CEO. &quot;While we have more work to do, we are confident we can achieve full-year revenue growth and meet our adjusted free cash flow target in 2021.&rdquo;
IBM shares opened for trading at $145.11, slightly below its 52-week high of $148.74 than to its 52-week low of $105.92.
See Also: <a href="https://www.youtube.com/watch?v=HcYVcT8GChY">Benzinga Stock Market Live: Get Technical</a>
A Cleaner Copy: Founded in 1906 as the Haloid Photographic Company, Xerox&rsquo;s headquarters in Norwalk, Connecticut, is roughly a half-hour drive from the IBM headquarters, but the two companies have been worlds removed in terms of corporate focus.
<img alt="320px-xerox_logo.svg_1.png" src="https://www.benzinga.com/files/u200644/320px-xerox_logo.svg_1.png" style="height:70px; width:320px" />
Xerox&rsquo;s problems started three years ago when the company was on track to be acquired by Japan&#39;s Fujifilm Holdings Corp (OTC: <a class="ticker" href="https://www.benzinga.com/stock/fujiy#OTC">FUJIY</a>) in a $6.1 billion deal. The&nbsp;transaction was canceled due to the machinations of shareholders Carl Icahn and Darwin Deason, who also managed to replace the company&rsquo;s leadership with executives they preferred. By the time this contentious issue was settled in November 2019, Xerox turned its attention to a hostile takeover of HP Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hpq#NYSE">HPQ</a>). The company ceased its efforts when the COVID-19 pandemic took root.
Last fall, Xerox&rsquo;s tech cred took a PR hit over a pair of widely reported cybersecurity breaches, a situation made all the more embarrassing because Xerox has sought to position itself as a cybersecurity expert. Adding to the mayhem was Icahn&rsquo;s mysterious insistence on increasing his stake in the company, which ballooned from 12.82% ownership in August 2020 to 17% in February 2021.
Still, the company has sought to maintain a proactive strategy in the face of its struggles. In February, it announced it would three create new businesses &mdash;&nbsp;Software, Financing and Innovation &mdash;&nbsp;although details on whether these will become separate entities like IBM&rsquo;s Kyndryl or subsidiaries has not been stated.
This year saw the company go&nbsp;on acquisition mini-spree by purchasing the augmented reality company CareAR in January and the Quebec-based document management provider Groupe CT Inc. in April; another Canadian firm, the software services provider Digitex Canada, was acquired in March 2020.
For its Q1 earnings, Xerox reported $1.71 billion of revenue, down 8.1% year-over-year, as well as $39 million in net income compared to a $2 million loss in Q1 2020. Its&rsquo; GAAP EPS was 18 cents, up 21 cents year-over-year, and its adjusted EPS was 22 cents, up by a penny from one year earlier.
Among its segments, Xerox&rsquo;s equipment sales generated $381 million in the first quarter, up from $325 million one year earlier. But revenues from its services, maintenance and rentals fell to $1 billion from the previous year&rsquo;s $1.2 billion and financing revenue dropped to $55 million from $59 million.
Still, CEO John Visentin remained optimistic, noting that as &ldquo;small and medium-sized business and enterprise clients planning to return more employees to the office, our differentiated offerings are well-positioned to serve their growing needs. The strength of our performance, portfolio and strategy give us confidence we will return Xerox to growth in 2021.&rdquo;
Xerox shares opened for trading at $24.31, much closer to its 52-week high of $26.96 than its 52-week low of $14.51.
The Verdict: Xerox attributed its wobbly Q1 to the continued closure of many offices as a result of the pandemic, but one can easily imagine a more vibrant earnings report in Q2 and Q3 as the increased levels of vaccinations and the return to increased levels of pre-pandemic normalcy takes root.
As for IBM, it is difficult to imagine what will take place once Kyndryl is fully spun off &mdash;&nbsp;tech industry reaction was mild, at best. And even though it offers cutting-edge solutions on cybersecurity, cloud computing and artificial intelligence, IBM doesn&rsquo;t quite captivate the way that the FAANG stocks command attention.
Nonetheless, IBM is in a stronger financial position compared to Xerox. And if it is not today&rsquo;s bright shiny object, it&#39;s nonetheless a solid and reliable addition to a portfolio.
What is your opinion on an IBM-Xerox stock duel? Share your thoughts at <a href="mailto:editorial@benzinga.com">editorial@benzinga.com</a> and <a href="mailto:philhall@benzinga.com">philhall@benzinga.com</a>.)
(Illustration by Mohamed Hassan / Pixabay.)

Long Ideas

Education

Opinion

Stock Wars: IBM Vs. Xerox

Xerox Holdings Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xrx#NYSE">XRX</a>) ended its fourth quarter with a weaker financial picture and the expressed hope for a more solid 2021.
What Happened:&nbsp;The Norwalk, Connecticut-based company reported $77 million in fourth-quarter net profits Tuesday, a far cry from the $818 million it reported one year earlier.
The quarter&#39;s $1.93 billion in revenue represented a 21% year-over-year tumble, while the earnings of 58 cents per share were&nbsp;56% lower year-over-year.
The fourth quarter also saw the company shedding 750 positions worldwide, which gave Xerox a total global workforce reduction of 2,300 for the year.
Why It&#39;s Important:&nbsp;While Xerox&#39;s earnings report attributed much of its problems to the ongoing COVID-19 pandemic, which saw the rise of a remote workforce that did not require its office-centric technologies while working from home, many of the company&#39;s problems preceded the health crisis.
At the start of 2020, Xerox had managed to reach an amicable resolution with Japan&#39;s Fujifilm Holdings (Pink: <a class="ticker" href="https://www.benzinga.com/stock/fujiy#Pink">FUJIY</a>) following the contentious and litigious cancellation of their planned merger. But no sooner was Fujifilm Holdings in Xerox&#39;s rear-view mirror than it began to chase after HP Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hpq#NYSE">HPQ</a>) in a hostile takeover that consisted of veiled public threats, brash displays of financial prowess and even the promise of free dinners for HP shareholders at a ritzy restaurant in the pricey New York suburb of Greenwich, Connecticut.
HP greeted the effort with a mix of bafflement and indifference, and Xerox abruptly halted its plans when the COVID-19 pandemic took root, leaving it with a public relations disaster.
As the year progressed, Xerox continued to have an optics problem. Activist investor Carl Icahn, Xerox&#39;s largest shareholder, became the center of media attention by increasing his ownership stake with a robust acquisition of shares.
Icahn&#39;s cantankerous behavior was also responsible for ending the Fujifilm Holdings merger and encouraging the doomed pursuit of HP, which made his share-buying spree even more curious. Also giving Xerox black eyes were a pair of widely reported cybersecurity breaches last fall, which was rather embarrassing because Xerox was trying to position itself as a cybersecurity expert.
What&#39;s Next:&nbsp;Xerox Vice Chairman and CEO John Visentin used the fourth- quarter earnings call to accentuate the positive while admitting a return to growth was not in the cards for this first quarter of this year.
In 2021, Xerox expects revenue of at least $7.2 billion in constant currency; operating cash flow from continuing operations to total at least $600 million; and free cash flow of at least $500 million, the CEO said.
&quot;We believe this is achievable even in the unlikely scenario businesses don&#39;t start reopening in a meaningful way in the first half. The benefit of a solid strategy is it&#39;s flexible in its application, yet strong in its foundation,&quot; he said.
Visentin also promised that 2021 will see the company &quot;adding workflow automation, machine learning, artificial intelligence and remote services to make our clients [and]&nbsp;employees&nbsp;more efficient while maintaining security.&quot;
Xerox&#39;s &quot;strong cash position provides flexibility to explore a wide range of M&amp;A opportunities,&quot; Visentin said.
Without mentioning Fujifilm Holdings or HP, Visentin held out the hope that the third time would be the charm for growing the company by uniting with another.

Xerox Looks Past Q4 For Stronger 2021

<a href="https://asia.nikkei.com/Business/Biotechnology/Fujifilm-to-make-Novavax-coronavirus-vaccine-component-in-UK">https://asia.nikkei.com/Business/Biotechnology/Fujifilm-to-make-Novavax-coronavirus-vaccine-component-in-UK</a>

NVAX

'Fujifilm to make Novavax coronavirus vaccine component in UK' -Nikkei Asian Review Report

Pre-Market Outlook

ACCD

AEYE

ALTG

ALYA

AMAT

AMTX

APTX

ARAY

AZEK

AZRE

AZUL

BIDU

BIOL

BLIN

BLNK

BNGO

BOXL

BSQR

CALT

CLBS

CNSP

CODX

CREX

CSSE

CTEK

CWBR

DCTH

DDEJF

DGLY

DRAD

DSSI

DTEGY

DTIL

DYAI

EAST

ECOR

EMAN

ESLT

FTCH

FUTU

GLNG

GLOB

GMLP

GTIM

Hollsys Automation Technologies INTERNATIONAL

HOLI

HOOK

HSTO

HYRE

IGXT

IIVI

INFU

INPX

INSE

INUV

IOCJY

IPWR

ITPOF

IZEA

JAGX

JRSH

LEAT

LIFE

LIZI

LUMO

MAGS

MEDIF

MGIC

MSGN

MTBC

MYGN

NAVB

NNDM

NTES

NVGS

PASG

PAYS

PDSB

PHGE

PROG

QRHC

REDU

RKDA

SCMWY

Earnings Scheduled For August 13, 2020

Trump: HHS, FUJIFILM Signed A Contract On Vaccine Manufacturing

Dr. Reddy's Laboratories Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rdy#NYSE">RDY</a>) announces partnering with FUJIFILM Corporation through FUJIFILM Toyama Chemical Co. Ltd. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/fujiy#OTC">FUJIY</a>) and Global Response Aid (hereafter referred to as "GRA") for the development, manufacture and sales of Avigan&#174; Tablets (generic name: favipiravir), a potential treatment of COVID-19.
Under the tripartite agreement signed on 30th June 2020, FUJIFILM grants Dr. Reddy's the exclusive rights of manufacturing and also grants both Dr. Reddy's and GRA the rights to develop, sell and distribute Avigan&#174; in all countries other than Japan, China and Russia. Dr. Reddy's would have exclusive rights for development, selling and distribution of Avigan&#174; in India. Further, FUJIFILM would receive an upfront license fee and royalties on sales from Dr. Reddy's and GRA.
FUJIFILM will provide Dr. Reddy's and GRA with an array of data on Avigan&#174;'s preclinical and clinical studies that FUJIFILM has accumulated thus far. Dr. Reddy's and GRA will use this data for clinical studies targeting COVID-19 in regions where infection has been spreading. In addition, FUJIFILM will grant Dr.Reddy's right to use Avigan&#174;'s patents of formulation and manufacturing method. Dr. Reddy's will herewith establish a setup for manufacturing drugs of the same quality as Avigan&#174;, and utilize GRA's global sales network to supply the manufactured drugs swiftly and in a stable manner.
The FUJIFILM Group is currently conducting a clinical study on Avigan&#174; targeting COVID-19 patients in Japan and the US, and is working to increase the drug's production by partnering with domestic and overseas companies. Dr. Reddy's and GRA shall introduce the product in the market post all applicable approvals in the respective countries.

Dr. Reddy's Partners with FUJIFILM and Global Response Aid for Avigan (favipiravir), a Potential Treatment of COVID-19

<h3>Companies Reporting Before The Bell</h3>
<ul>
<li>Alibaba Group Holding Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/baba#NYSE">BABA</a>) is estimated to report quarterly earnings at $0.87 per share on revenue of $15.20 billion.</li>
<li>Foot Locker Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fl#NYSE">FL</a>) is estimated to report quarterly earnings at $0.49 per share on revenue of $1.58 billion.</li>
<li>Deere Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/de#NYSE">DE</a>) is estimated to report quarterly earnings at $1.80 per share on revenue of $7.76 billion.</li>
<li>Buckle Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bke#NYSE">BKE</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $143.23 million.</li>
<li>CAE Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cae#NYSE">CAE</a>) is expected to report quarterly earnings at $0.25 per share on revenue of $611.18 million.</li>
<li>iClick Interactive Asia Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iclk#NASDAQ">ICLK</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $47.04 million.</li>
<li>Pinduoduo Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pdd#NASDAQ">PDD</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $704.20 million.</li>
<li>FUJIFILM Holdings Inc. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/fujiy#OTC">FUJIY</a>) is estimated to report quarterly earnings at $0.87 per share on revenue of $5.78 billion.</li>
</ul>
<h3>
Companies Reporting After The Bell</h3>
<ul>
<li>Natuzzi S.p.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ntz#NYSE">NTZ</a>) is estimated to post earnings for its fourth quarter.</li>
</ul>

BABA

ICLK

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Earnings Scheduled For May 22, 2020

<a href="https://www.politico.com/news/2020/03/31/white-house-pressures-fda-japanese-drug-157587" title="https://www.politico.com/news/2020/03/31/white-house-pressures-fda-japanese-drug-157587">https://www.politico.com/news/2020/03/31/white-house-pressures-fda-japanese-drug-157587</a>

Global

'White House pressures FDA on unproven Japanese drug' - POLITICO

A senior research analyst at Piper Sandler believes Gilead Sciences Inc.&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gild#NASDAQ">GILD</a>) Remdesivir antiviral may soon be approved for COVID-19 treatment.
<h3>The Gilead Analyst</h3>
<a href="https://www.tipranks.com/analysts/tyler-van-buren">Tyler Van Buren</a> maintains a Neutral rating on Gilead with a price target of $70.
<h3>The Gilead Thesis</h3>
Remdesivir has been shown to be effective against COVID-19. Clinical data indicates Remdesivir is safer than alternative Favipiravir and also more effective. Van Buren said data gathered from 200 patients is &ldquo;highly encouraging&rdquo; and Remdesivir drug trials are positive.
Trials conducted in China and Japan indicate that Favipiravir, which is&nbsp;manufactured by Toyama Chemical Co. owned by FUJIFILM Holdings Corp (OTC: <a class="ticker" href="https://www.benzinga.com/stock/fujiy#OTC">FUJIY</a>) under the brand name Avigan, also has <a href="https://www.benzinga.com/news/20/03/15577152/fujifilm-shares-skyrocket-as-china-says-its-flu-medicine-works-for-coronavirus">efficacy</a> against RNA viruses. The drug is somewhat effective in treating COVID-19,&nbsp;but needs to be used early on, according to Japanese officials.
Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, <a href="https://benzinga.us7.list-manage.com/subscribe?u=360cb137f817ffe23656afe49&amp;id=e57f24ad9b">sign up for our coronavirus newsletter</a>.
Van Buren said there are currently five&nbsp;Remdesivir trials underway, of which two are in China. China&rsquo;s test results should be out by the end of the month. Gilead&rsquo;s own two trial results will follow next. These are shorter 14-day trials but with restrictive entry criteria. A 30-day NIAID Hospitalized US Adult Phase II trial is also being carried out to measure Remdesivir&rsquo;s efficacy against a placebo.
Remdesivir is likely to be approved for broad use in the coming months, Van Buren wrote in a note. Due to the COVID-19 epidemic, the U.S.&nbsp;Food and Drug Administration may consider fast-tracking approval.
<h3>GILD Price Action</h3>
Gilead shares traded 1.6% higher Thursday morning. The stock closed Wednesday&#39;s session 6.58% higher at $79.42.

Analyst Color

Analyst Ratings

GILD

Analyst Says Gilead's Remdesivir Could Be Approved 'Within Months' For COVID-19 Treatment

The shares of FUJIFILM Holdings Corporation (OTC: <a class="ticker" href="https://www.benzinga.com/stock/fujiy#OTC">FUJIY</a>) hit their daily permissible high limit on Wednesday&#39;s open in Tokyo.
<h3>What Happened</h3>
The massive jump in an otherwise bearish market came as China suggested that an influenza medicine developed by subsidiary FUJIFILM Toyama Chemical Co. Ltd. is also effective against the novel coronavirus (COVID-19).
&quot;It has a high degree of safety and is clearly effective in treatment,&quot; the director of the Chinese science ministry&#39;s China National Center for Biotechnology Development, Zhang Xinmin said, <a href="https://asia.nikkei.com/Spotlight/Coronavirus/China-says-Japan-developed-drug-Avigan-works-against-coronavirus">according</a> to the Nikkei Asian Review.
Japan has been administering the medicine to coronavirus patients since February, The Nikkei noted. Toyama Chemical developed the drug, sold under the brand name Avigan, in 2014 as a medicine to combat the flu.
<h3>Why It Matters</h3>
Zhejiang Hisun Pharmaceutical Co Ltd, which signed a patent-licensing agreement with Fujifilm for the generic drug Favipiravir, received approval from Chinese authorities in February to conduct clinical trials for effectiveness against COVID-19, as <a href="https://www.reuters.com/article/brief-corrected-zhejiang-hisun-pharma-ge/brief-corrected-zhejiang-hisun-pharma-gets-approval-for-clinical-trial-to-test-flu-drug-favipiravir-for-pneumonia-caused-by-new-coronavirus-idUSL4N2AH0C8">reported</a> by Reuters at the time.
About 200 patients at hospitals in Chinese cities of Wuhan and Shenzhen are said to have participated in the trials, according to the Nikkei.
The spread of the coronavirus has slowed down drastically in China to double-digits, with a total of 81, 086 cases, according to data from Johns Hopkins University. More than 3,200 people have died from COVID-19 in China, and another 4,713 have died outside the country.
<h3>Price Action</h3>
Fujifilm&#39;s shares traded 15.43% higher at $48.94 in Tokyo at press time on Wednesday. The shares closed 19.51% higher at $47.90 in the otc market on Tuesday.

Comments

FUJIFILM Holdings

FUJIFILM Holdings (FUJIY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga